ERA Testing for IVF: Is It Worth the Cost?

The Endometrial Receptivity Analysis—ERA test—is one of the most commonly offered add-ons in IVF. Its promise is straightforward: by biopsying your uterine lining and analyzing the expression of 238 genes, the test identifies your personal “window of implantation” so your embryo transfer can be timed to the exact hour your endometrium is most receptive.

It sounds like precision medicine at its best. The cost is $800 to $1,500 per biopsy, plus the expense of a mock cycle to obtain the sample. And fertility clinics across the country offer it routinely—often to patients who have experienced even a single failed transfer.

But what does the evidence actually show? The answer is more complicated—and less encouraging—than most clinics communicate.

What the ERA Test Claims to Do

The concept behind ERA testing is biologically plausible. The “window of implantation” (WOI) is a short period—roughly 12 to 48 hours—during which the uterine lining shifts into a receptive state that allows a blastocyst to implant. If this window is displaced (occurring earlier or later than expected), an embryo transferred at the standard timing would arrive when the lining isn’t ready.

ERA testing analyzes a biopsy of your endometrium for the expression of 238 genes associated with receptivity, then classifies your sample as “receptive” (your window aligns with standard timing), “pre-receptive” (your window is later than expected), or “post-receptive” (your window has already passed). If your result is non-receptive, the test recommends adjusting the timing of your progesterone exposure to shift your transfer to match your personal window.

Approximately 12–25% of patients tested are classified as having a displaced window of implantation. The test is developed and marketed by Igenomix (now part of Vitrolife), and it has become one of the most widely offered IVF add-ons globally.

What the Evidence Actually Shows

This is where the gap between marketing and data becomes significant.

The Key Trial: No Benefit in the General IVF Population

The largest and most rigorous randomized controlled trial (RCT) on ERA testing was presented at the 2021 American Society for Reproductive Medicine (ASRM) Scientific Congress. It found that ERA-guided personalized embryo transfer did not significantly improve live birth rates compared to standard transfer timing in the general IVF population.

This finding was consistent with a 2018 study that concluded performing the ERA test does not appear to improve ongoing pregnancy rates. A systematic review and meta-analysis of available trials confirmed that ERA testing does not appear to affect the chance of having a baby from IVF, with the evidence graded as low to moderate quality.

What About Recurrent Implantation Failure?

The most common clinical scenario for ERA testing is the patient who has had two or more failed transfers with good-quality, often PGT-A-tested embryos. The logic seems compelling: if good embryos keep failing to implant, maybe the timing is off.

Some observational studies and retrospective analyses suggest a benefit of ERA-guided transfer for RIF patients. But observational data in this context is particularly unreliable, because patients with recurrent failures who undergo any additional testing or protocol change—ERA or otherwise—tend to have better outcomes in subsequent cycles for reasons that may have nothing to do with the specific intervention. This is a well-known phenomenon called “regression to the mean.”

Until a properly powered RCT specifically enrolls RIF patients and randomizes them to ERA-guided versus standard-timed transfer, the honest answer is: we don’t know whether ERA helps this population. The biological rationale is plausible. The evidence is inconclusive.

Regulatory Perspective

The UK’s Human Fertilisation and Embryology Authority (HFEA), which rates IVF add-ons on a traffic-light system based on evidence quality, has not given ERA testing a green light. Their assessment: add-ons without strong evidence of safety and effectiveness should only be offered in research settings like clinical trials. The HFEA’s position is not that ERA testing is harmful—it’s that the evidence does not yet support routine clinical use.

The Cost-Benefit Calculation

ERA testing typically costs $800 to $1,500 for the biopsy analysis, plus the cost of a mock cycle to obtain the sample. A mock cycle involves the same medication protocol as a frozen embryo transfer cycle but without actually transferring an embryo—meaning you pay for medications, monitoring appointments, and a month of time. All-in, the cost of ERA testing is typically $2,000 to $4,000 when you include the mock cycle.

The biopsy itself is a brief office procedure but can be painful (comparable to an IUD insertion). Most patients describe it as 15–30 seconds of significant cramping.

For a patient who is already spending $15,000–$25,000 per IVF cycle, adding $2,000–$4,500 for a test that might not change outcomes is a meaningful financial decision—especially when many patients are paying out of pocket and every dollar counts.

When ERA Testing Might Be Reasonable

Despite the lack of strong RCT evidence, there are clinical scenarios where ERA testing is at least defensible:

Multiple failed transfers with euploid embryos. If you’ve transferred two or more PGT-A normal embryos and neither implanted, the list of possible explanations is short. Displaced implantation window is one of them. In this scenario, the test addresses a specific clinical question rather than fishing for information.

When the opportunity cost of another failed transfer is very high. If you have only one or two remaining embryos, or if each additional cycle represents a disproportionate financial or emotional burden, the relatively modest cost of ERA testing may feel justified as a way to optimize your remaining chances.

When your RE specifically recommends it based on your clinical picture. Some reproductive endocrinologists have clinical experience suggesting ERA testing changes outcomes for specific patient profiles. Anecdotal evidence is not the same as trial evidence, but a personalized recommendation from a physician who knows your case carries more weight than a blanket clinic protocol.

When ERA Testing Is Probably Not Worth It

After a single failed transfer. One failed transfer is not diagnostic of anything. Most first transfers with good-quality embryos fail for stochastic reasons—the same kind of chance variation that makes any single month of trying unlikely to result in pregnancy. Adding ERA testing after one failure is premature and adds cost without strong clinical justification.

As a routine part of every IVF cycle. Some clinics recommend ERA testing as standard protocol for all FET patients. The RCT evidence does not support this. In the general IVF population, ERA-guided transfer does not improve outcomes over standard timing.

When you haven’t done PGT-A testing. If your failed transfers involved untested embryos, the most likely explanation for failure is embryo aneuploidy (chromosomal abnormality), not transfer timing. Chromosomal abnormalities account for the majority of implantation failures, especially in patients over 35. Addressing the embryo question (via PGT-A) before the endometrial question (via ERA) is a more logical sequence.

Questions to Ask Your RE About ERA Testing

If your clinic recommends ERA testing, ask: What is the specific clinical indication for this test in my case? Has this test been studied in a randomized trial for patients like me? What will you do differently based on the result? If the result comes back “receptive” (which it does approximately 75–88% of the time), what have I gained? What is the total cost including the mock cycle? Are there other explanations for my failed transfers that we should investigate first?

Alternatives to ERA for Investigating Implantation Failure

If you’ve experienced repeated implantation failure, ERA testing is not the only avenue of investigation—and in some cases, it may not even be the most productive one. Before spending $2,000–$4,500 on a test with uncertain evidence, consider whether these alternatives have been adequately explored:

Hysteroscopy. A direct visual examination of the uterine cavity can identify structural issues—polyps, fibroids, adhesions, or a uterine septum—that interfere with implantation and are treatable. Many reproductive endocrinologists consider hysteroscopy a more evidence-based first step than ERA for patients with unexplained implantation failure.

Thyroid and autoimmune screening. Subclinical thyroid dysfunction and certain autoimmune antibodies (particularly antiphospholipid antibodies) can contribute to implantation failure and early pregnancy loss. These are inexpensive blood tests with well-established treatment protocols when positive.

Sperm DNA fragmentation testing. When the focus is entirely on the endometrium, sperm quality as a contributor to implantation failure is sometimes overlooked. High sperm DNA fragmentation can result in embryos that look normal on morphological grading but fail to implant or develop normally. This test is typically $200–$400 and may identify a correctable contributing factor.

Reassessing embryo quality. If your failed transfers used morphologically graded (but not PGT-A tested) embryos, the most statistically likely explanation for failure remains chromosomal abnormality—not endometrial timing. In a 40-year-old patient, more than 60% of embryos may be aneuploid regardless of how they look under the microscope. PGT-A testing addresses this directly.

The Bigger Picture: IVF Add-Ons and Evidence

ERA testing is one of dozens of IVF add-ons that have become standard practice at many clinics despite limited evidence. Others include endometrial scratch, intralipid infusions, and various immune protocols. The pattern is consistent: a biologically plausible mechanism, early observational data that looks promising, aggressive marketing to vulnerable patients, and a lack of large-scale RCTs to confirm or deny benefit.

The HFEA in the United Kingdom has developed a traffic-light rating system for IVF add-ons, categorizing each based on the strength of evidence behind it. ERA testing has not earned a green rating. This doesn’t mean the test is useless—it means the evidence base is not yet strong enough to recommend it as a routine clinical tool. The distinction matters.

Patients navigating the IVF add-on landscape should apply a consistent standard: ask for the specific clinical indication in your case, ask whether the intervention has been validated in randomized trials for patients with your profile, and ask what changes to your treatment plan will result from the findings. Any add-on that cannot clearly answer these three questions deserves skepticism, regardless of how scientifically plausible the mechanism sounds.

This doesn’t mean these interventions are scams. Some may prove genuinely useful when properly studied. But the gap between what we know and what clinics imply we know is real, and patients deserve to understand it before spending money on unproven additions to an already expensive treatment.

For a similar evidence-based look at another common add-on, see our guide to whether PGT-A testing is worth the cost. And for patients evaluating their overall IVF plan, our week-by-week IVF timeline and mini IVF vs. conventional comparison provide additional framework.